Klerimed

Clarithromycin, the active ingredient in Klerimed, is a macrolide antibiotic presented as an oral dosage form for systemic use. It treats a range of bacterial infections, including respiratory, sinus, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Klerimed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic indicated for several bacterial infections affecting the respiratory and gastrointestinal tracts as well as skin structures. - Community‑acquired pneumonia: effective treatment of susceptible bacterial pneumonia in adults. - Acute bacterial sinusitis: resolves infection of the sinus cavities caused by susceptible organisms. - Acute bacterial exacerbations of chronic bronchitis: reduces bacterial load during flare‑ups. - Skin and soft‑tissue infections: treats cellulitis, erysipelas and other infections caused by susceptible bacteria. - Helicobacter pylori eradication (in combination therapy): part of triple or quadruple regimens to eliminate H. pylori infection.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools often occurring early in therapy. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste perception. - Headache: mild to moderate tension‑type headache. - Vomiting: occasional episodes of emesis.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - QT prolongation: cardiac rhythm disturbance that may lead to arrhythmia. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Clostridioides difficile infection: severe colitis associated with antibiotic use. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction. - Severe neutropenia: marked reduction in white blood cells.

Before prescribing clarithromycin, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: use with caution in patients with liver disease. - Cardiac risk: avoid in patients with known QT prolongation or arrhythmias. - Drug interactions: review concomitant medications for potential interactions. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Clarithromycin interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Erythromycin: combined use increases risk of cardiac arrhythmias. - Cisapride: may cause severe QT prolongation. - Theophylline: clarithromycin can raise serum theophylline levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Simvastatin: increased risk of myopathy; consider dose reduction. - Carbamazepine: may reduce clarithromycin concentrations, decreasing efficacy.